Foster Group Inc. Acquires Shares of 13,704 Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Foster Group Inc. bought a new position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 13,704 shares of the company’s stock, valued at approximately $216,000.

Several other hedge funds have also modified their holdings of RDY. Farther Finance Advisors LLC raised its holdings in Dr. Reddy’s Laboratories by 43.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after purchasing an additional 137 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Dr. Reddy’s Laboratories during the third quarter worth approximately $60,000. Van ECK Associates Corp lifted its holdings in Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after buying an additional 322 shares during the period. GAMMA Investing LLC boosted its stake in Dr. Reddy’s Laboratories by 369.9% in the fourth quarter. GAMMA Investing LLC now owns 6,799 shares of the company’s stock valued at $107,000 after acquiring an additional 5,352 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Dr. Reddy’s Laboratories during the 4th quarter worth $145,000. 3.85% of the stock is owned by institutional investors.

Dr. Reddy’s Laboratories Trading Up 0.1 %

Shares of NYSE RDY opened at $13.55 on Thursday. Dr. Reddy’s Laboratories Limited has a twelve month low of $13.36 and a twelve month high of $16.89. The stock has a market cap of $11.31 billion, a price-to-earnings ratio of 21.64 and a beta of 0.51. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average is $14.82 and its 200-day moving average is $15.47.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 18.53% and a net margin of 17.81%. Equities research analysts predict that Dr. Reddy’s Laboratories Limited will post 0.81 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on RDY. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Finally, Barclays decreased their target price on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.